• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices

LifeCell Corp.

Allergan closes $3B Acelity LifeCell buy

February 1, 2017 By Sarah Faulkner

Acelity said today that it closed the sale of its regenerative medicine unit, LifeCell, to Allergan (NYSE:AGN) for $2.9 billion in cash. The deal brings LifeCell’s regenerative medicine and reconstructive portfolio to Allergan, joining a portfolio of medical aesthetics, breast implant and tissue expander product lines. Dublin-based Allergan said it expects to bring in $450 million in revenue this year, growing […]

Filed Under: Mergers & Acquisitions, Regenerative Medicine, Wall Street Beat, Wound Care Tagged With: Acelity, Allergan, LifeCell Corp.

Allergan picks up Acelity’s LifeCell biz for $2.9B

December 20, 2016 By Fink Densford

Acelity said today that it inked a definitive agreement with Allergan (NYSE:AGN) to sell its LifeCell business for $2.9 billion in cash. The deal will put LifeCell’s regenerative medicine and reconstructive portfolio under Allergan’s roof, joining its medical aesthetics, breast implant and tissue expander product lines. Dublin-based Allergan said it expects will generate approximately $450 million in […]

Filed Under: Business/Financial News, Mergers & Acquisitions, Regenerative Medicine Tagged With: Acelity, Allergan, LifeCell Corp.

Tela Bio, Acelity’s LifeCell settle patent spat

November 21, 2016 By Brad Perriello

Tela Bio and Acelity subsidiary LifeCell settled their patent infringement beef last month for terms that were not disclosed. Malvern, Pa.-based Tela Bio said the settlement puts to bed all state and federal court cases between the companies and allows it to keep making its OviTex line of reinforced scaffolds for abdominal surgery. “We are very pleased that we were able […]

Filed Under: Legal News, Surgical Tagged With: Acelity, LifeCell Corp., Tela Bio

Allergan CEO Pyott steps down from Edwards Lifesciences board | Personnel Moves

October 7, 2014 By Brad Perriello Leave a Comment

Allergan CEO Pyott steps down from Edwards Lifesciences board | Personnel Moves


Filed Under: News Well Tagged With: Acelity, Allergan, Bio-Rad, Boston Scientific, Edwards Lifesciences, LensAR Inc., LifeCell Corp., Personnel Moves, Polaris Industries, Premier Inc., Sensory Medical, SiBone, STAAR Surgical Co, Thoratec Corp.

Failure of Medtronic’s Symplicity-3 trial doesn’t mean the end of renal denervation for hypertension | Medtech Wall Street news for the week of September 1, 2014

September 4, 2014 By MassDevice Contributors Network Leave a Comment

Renal denervation isn't dead, despite Medtronic trial's failure

September 2, 2014 by Brad Perriello

Filed Under: News Well, Wall Street Beat Tagged With: Acelity, Apax Partners, Baxter, Boston Scientific, Centaur Guernsey, Covidien, Kinetic Concepts Inc., Kona Medical, LifeCell Corp., ReCor Medical, stjudemedical, Systagenix Wound Management Inc.

Private equity owners rebrand KCI, Systagenix, LifeCell as Acelity

September 3, 2014 By Brad Perriello Leave a Comment

Private equity owners rebrand KCI, Systagenix, LifeCell as Acelity

The private equity owners of a trio of wound care and regenerative medicine companies said today that they’re merging Kinetic Concepts Inc., Systagenix and LifeCell into a single entity called Acelity.

Filed Under: News Well, Regenerative Medicine, Wall Street Beat Tagged With: Acelity, Apax Partners, Centaur Guernsey, Kinetic Concepts Inc., LifeCell Corp., Marketing/Public Relations, Systagenix Wound Management Inc., Wound Therapy

Kinetic Concepts, LifeCell, Systagenix trio posts red ink in Q4

March 10, 2014 By Arezu Sarvestani Leave a Comment

Kinetic Concepts, LifeCell, Systagenix trio posts red ink in Q4

The newly formed medtech alliance comprised of Kinetic Concepts, LifeCell and Systagenix posted collective figures that put the group in the red for Q4, a recent SEC filing shows.

Filed Under: MassDevice Earnings Roundup, News Well, Regenerative Medicine Tagged With: 2013, Centaur Guernsey, Kinetic Concepts Inc., LifeCell Corp., Q4, Systagenix Wound Management Inc., Wound Therapy

Kinetic Concepts touts tissue injector acquisition

January 28, 2014 By Arezu Sarvestani Leave a Comment

Kinetic Concepts touts tissue injector acquisition

Kinetic Concepts sister company LifeCell this week announced the acquisition of fat-injection devices from California medtech group TauTona.

LifeCell hopes to use the deal, the details of which were not disclosed, to expand its reconstructive and cosmetic portfolio with the fat grafting technology.

Filed Under: Cosmetic/Aesthetic, Mergers & Acquisitions, News Well Tagged With: Kinetic Concepts Inc., LifeCell Corp., Systagenix Wound Management Inc., TauTona Group

Kinetic Concepts slips in Q3, losses widen for Systagenix, LifeCell triad

November 13, 2013 By Arezu Sarvestani Leave a Comment

Kinetic Concepts announces 1st quarter as part of Centaur Guernsey

Sales took a minor hit for Kinetic Concepts during its 3rd quarter 2013, reporting as part of the Centaur Guernsey companies which now includes both LifeCell and Systagenix.

Filed Under: MassDevice Earnings Roundup, News Well, Regenerative Medicine Tagged With: 2013, Centaur Guernsey, Kinetic Concepts Inc., LifeCell Corp., Q3, Systagenix Wound Management Inc., Wound Therapy

KCI closes $485M buyout of Systagenix

October 28, 2013 By Brad Perriello Leave a Comment

KCI closes $485M buyout of Systagenix
KCI closes $485M buyout of Systagenix

Kinetic Concepts Inc. said it’s closed the $485 million buyout of fellow privately owned wound-care company Systagenix, which it plans to unite with its LifeCell regenerative therapies unit.

Filed Under: Mergers & Acquisitions, News Well Tagged With: Kinetic Concepts Inc., LifeCell Corp., Systagenix Wound Management Inc., Wound Therapy

Kinetic Concepts forms trinity with LifeCell and Systagenix

September 30, 2013 By Arezu Sarvestani Leave a Comment

Kinetic Concepts forms trinity with LifeCell and Systagenix

Just weeks after the $485 million merger of Kinetic Concepts and Systagenix, the duo plans to merge forces with LifeCell Corp., forming a 3-headed hydra of wound care, biologics and regenerative therapies.

The new company will be run by KCI president & CEO Joe Woody, with LifeCell commercial operations chief Phil Croxford as senior vice president and "permanent leader" of LifeCell, according to a joint statement.

Filed Under: Mergers & Acquisitions, News Well, Regenerative Medicine Tagged With: Kinetic Concepts Inc., LifeCell Corp., Negative-Pressure Wound Therapy, Systagenix Wound Management Inc., Wound Therapy

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy